BVS (STOCKS)
Bioventus Inc. Class A Common Stock
$9.420000
+0.360000 (+3.97%)
Prev close: $9.060000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Robert Claypoole
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $783.73M
- Employees
- 950
- P/E (TTM)
- 28.55
- P/B (TTM)
- 3.43
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.24 | $0.22 | +0.0212 | +9.69% |
|
Sep 2025 (Q3)
|
$0.15 | $0.12 | +0.0338 | +29.09% |
|
Jun 2025 (Q2)
|
$0.21 | $0.21 | -0.0021 | -0.99% |
|
Mar 2025 (Q1)
|
$0.08 | $0.02 | +0.0564 | +238.98% |
Financial Statements
| Revenues | $568.09M |
| Benefits Costs and Expenses | $542.38M |
| Cost Of Revenue | $179.93M |
| Costs And Expenses | $542.38M |
| Gross Profit | $388.16M |
| Nonoperating Income/Loss | -$28.27M |
| Operating Expenses | $334.18M |
| Selling, General, and Administrative Expenses | $314.03M |
| Depreciation and Amortization | $5.73M |
| Research and Development | $12.11M |
| Other Operating Expenses | $2.32M |
| Operating Income/Loss | $53.98M |
| Income/Loss From Continuing Operations After Tax | $27.27M |
| Income/Loss From Continuing Operations Before Tax | $25.71M |
| Income/Loss From Discontinued Operations Net Of Tax | $0.00 |
| Income Tax Expense/Benefit | -$1.57M |
| Income Tax Expense/Benefit, Current | -$656.00K |
| Income Tax Expense/Benefit, Deferred | -$909.00K |
| Net Income/Loss | $27.27M |
| Net Income/Loss Attributable To Noncontrolling Interest | $4.54M |
| Net Income/Loss Attributable To Parent | $22.73M |
| Net Income/Loss Available To Common Stockholders, Basic | $22.73M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.34 |
| Diluted Earnings Per Share | $0.33 |
| Basic Average Shares | 66,622,631 |
| Diluted Average Shares | 68,914,895 |
| Assets | $683.56M |
| Current Assets | $272.84M |
| Inventory | $82.24M |
| Other Current Assets | $190.61M |
| Noncurrent Assets | $410.72M |
| Intangible Assets | $368.42M |
| Other Non-current Assets | $42.30M |
| Liabilities | $455.11M |
| Current Liabilities | $160.38M |
| Accounts Payable | $10.93M |
| Other Current Liabilities | $149.45M |
| Noncurrent Liabilities | $294.73M |
| Equity | $228.45M |
| Equity Attributable To Noncontrolling Interest | $44.34M |
| Equity Attributable To Parent | $184.11M |
| Liabilities And Equity | $683.56M |
| Net Cash Flow From Operating Activities | $74.67M |
| Net Cash Flow From Operating Activities, Continuing | $74.67M |
| Net Cash Flow From Operating Activities, Discontinued | $0.00 |
| Net Cash Flow From Investing Activities | -$3.25M |
| Net Cash Flow From Investing Activities, Continuing | -$3.25M |
| Net Cash Flow From Investing Activities, Discontinued | $0.00 |
| Net Cash Flow From Financing Activities | -$62.14M |
| Net Cash Flow From Financing Activities, Continuing | -$62.14M |
| Exchange Gains/Losses | $371.00K |
| Net Cash Flow | $9.66M |
| Net Cash Flow, Continuing | $9.29M |
| Net Cash Flow, Discontinued | $0.00 |
| Comprehensive Income/Loss | $28.11M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $4.71M |
| Comprehensive Income/Loss Attributable To Parent | $23.41M |
| Other Comprehensive Income/Loss | $1.83M |